Tenaya Therapeutics Inc (TNYA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.37+2.66%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TNYA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“The forthcoming data updates from TN-201 and TN-401, together with regulatory feedback on potential pivotal development pathways, are expected to inform potential opportunities to advance these prog…
Stated in 3 of 3 supplied quarters. Management reported: “TN-401 – Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) • In September 2026, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401 for the treatment of PKP2 -associated ARVC.” “• Tenaya is in ongoing discussions with regulatory authorities with an additional interaction planned to explore late-stage pivotal trial plans for TN-201 and intends to provide an update by year end.” Revenue was $1.697 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““The forthcoming data updates from TN-201 and TN-401, together with regulatory feedback on potential pivotal development pathways, are expected to inform potential opportunities to advance these prog…”
“We are engaging with regulators to discuss the efficient late-stage development and approval pathways for each candidate.””
“Building on the encouraging initial readouts we reported in 2025, we believe the additional data expected this year from both TN-201 and TN-401 may support alignment on registrational pathways for th…”
• Research & Development (R&D) Expenses: R&D expenses were $14.9 million for the third quarter of 2026, compared to $15.4 million for the same period in 2025.
Stated in 2 of 3 supplied quarters. Management reported: “• Research & Development (R&D) Expenses: R&D expenses were $14.9 million for the third quarter of 2026, compared to $15.4 million for the same period in 2025.” “Exiting this lease is part of the company’s ongoing efforts to reduce costs.” Revenue was $1.697 million in 2026-Q3.
“• Research & Development (R&D) Expenses: R&D expenses were $14.9 million for the third quarter of 2026, compared to $15.4 million for the same period in 2025.”
“Exiting this lease is part of the company’s ongoing efforts to reduce costs.”
Tenaya expects that such resources will be sufficient to fund planned operations into the fourth quarter of 2027.
Stated in 3 of 3 supplied quarters. Management reported: “Tenaya expects that such resources will be sufficient to fund planned operations into the fourth quarter of 2027.” “Tenaya expects existing cash and cash equivalents will be sufficient to fund planned operations through Q3 of 2027.” Revenue was $1.697 million in 2026-Q3.
“Tenaya expects that such resources will be sufficient to fund planned operations into the fourth quarter of 2027.”
“Tenaya expects existing cash and cash equivalents will be sufficient to fund planned operations through Q3 of 2027.”
“Tenaya expects that such resources, along with the $10.0 million upfront payment from the Alnylam collaboration, will be sufficient to fund planned operations into the second half of 2027.”
The company intends to initiate at least one company-sponsored Phase 2 clinical trial in the second half of 2027.
Stated in 3 of 3 supplied quarters. Management reported: “The company intends to initiate at least one company-sponsored Phase 2 clinical trial in the second half of 2027.” “The company intends to share additional details regarding its TN-301 development plans in the fourth quarter of 2026, and to initiate at least one company-sponsored proof-of-activity Phase 2 clinical trial in the second half of 2027.”
“The company intends to initiate at least one company-sponsored Phase 2 clinical trial in the second half of 2027.”
“The company intends to share additional details regarding its TN-301 development plans in the fourth quarter of 2026, and to initiate at least one company-sponsored proof-of-activity Phase 2 clinical…”
“• In 2026, Tenaya plans to advance TN-301 toward clinical trials in patients in order to generate proof-of-activity data, with HFpEF and DMD being among the most promising potential indications ident…”
“The second quarter marked an important period of execution for Tenaya as we shared new safety and clinical benefit data for TN-201 and TN-401,” said Faraz Ali, Chief Executive Officer of Tenaya.
Over the trailing year it converted 0.86x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.